Group 1 - The core viewpoint of the news is that Xi'an Deyi Group Co., Ltd. has seen its Hong Kong IPO application expire after six months, with CITIC Securities International, Pudong Development Bank International, and Minyin Capital as joint sponsors [1] - Deyi Group is a global leader in innovative radiotherapy solutions, focusing on building a next-generation intelligent radiotherapy ecosystem since its establishment in 2011 [2] - The company's flagship product, CybeRay, is the world's first real-time image-guided gamma radiotherapy system, which received FDA and NMPA approvals in March 2021 and July 2022, respectively, and is currently in the research phase for expanding indications [2] - Another key product, TaiChiRT Pro, is the first integrated radiotherapy system to receive breakthrough medical device designation from the FDA [2]
新股消息 | 大医集团港股IPO招股书失效
智通财经网·2025-10-27 23:09